A Food and Drug Administration panel voted against Targanta Therapeutics Corp.'s (Nasdaq: TARG) injectable antibiotic oritavancin sending shares of the biopharmaceutical plummeting $6.43 to $1.33.
FDA Rejects Targanta Antibiotic
November 20, 2008 at 12:53 PM EST
